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Abstract Indoleamine 2,3-dioxygenase (IDO) is an
immunoregulatory enzyme that is implicated in suppress-
ing T-cell immunity in many settings including cancer. In
recent years, we have described spontaneous CD8? as well
as CD4? T-cell reactivity against IDO in the tumor
microenvironment of different cancer patients as well as in
the peripheral blood of both cancer patients and to a lesser
extent in healthy donors. We have demonstrated that IDO-
reactive CD8? T cells were peptide-specific, cytotoxic
effector cells, which are able to recognize and kill IDO-
expressing cells including tumor cells as well as dendritic
cells. Consequently, IDO may serve as a widely applicable
target for immunotherapeutic strategies with a completely
different function as well as expression pattern compared
to previously described antigens. IDO constitutes a sig-
nificant counter-regulatory mechanism induced by pro-
inflammatory signals, and IDO-based immunotherapy may
consequently be synergistic with additional immunother-
apy. In this regard, we have shown that the presence of
IDO-specific T cells boosted immunity against CMV and
tumor antigens by eliminating IDO? suppressive cells and
changing the regulatory microenvironment. The current
review summarizes current knowledge of IDO as a T-cell
antigen, reports the initial results that are suggesting a
general function of IDO-specific T cells in immunoregu-
lation, and discusses future opportunities.
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IDO and immune suppression
The immune system is delicately balanced between
immunity and tolerance to protect the host from pathogens
while minimizing local damage to tissues. Indoleamine
2,3-dioxygenase (IDO) is an endogenous molecular
mechanism that contributes to this immune regulation in a
variety of settings. IDO seems to be critical in limiting
potentially exaggerated inflammatory reactions in response
to danger signals [33] and in assisting regulatory T-cell
effector function [32]. In addition, IDO is an important
component of a regulatory system that allows long-term
control of immune homeostasis as may be required by
tolerance to self or during pregnancy [27].
IDO is a major inhibitor of the effector phase of the
immune response [45, 50]. IDO expression can suppress
effector T cells directly by degradation of the essential amino
acid tryptophan. Some of the biological effect of IDO is
mediated through local depletion of tryptophan, but is in
addition mediated via immune modulatory tryptophan
metabolites [4, 30]. Thus, regulation of tryptophan metabo-
lism by IDO in dendritic cells (DC) is a highly adaptable
modulator of immunity. When IDO? DC are injected in vivo,
they create suppression and anergy in antigen-specific T cells
in the LN draining the injection site [3, 25]. Effector T cells
starved of tryptophan are unable to proliferate and go into G1
cell cycle arrest [25]. An IDO-responsive signaling system in
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T cells has been identified, comprising the stress kinase GC
non-derepressing 2 kinase (GCN2). GCN2 responds to ele-
vations in uncharged tRNA, as would occur if the T cell were
deprived of tryptophan [24].
Another effect of IDO is mediated through enhancement
of local Treg-mediated immune suppression. Constitutive
IDO expression in DC provides T cells with regulatory
properties that block T-cell responses to antigenic stimu-
lation [24]. The B7 receptors on IDO? DC bind to CTLA4
on Tregs causing them to proliferate and induce antigen-
specific anergy. Thus, IDO does not only suppress effector
T cells directly but also influence Tregs bystander sup-
pressor activity [2, 32, 39].
It has been described that exposure of Tregs to pro-
inflammatory cytokines like IL-6 induce reprogramming of
mature Tregs to acquire a phenotype resembling pro-
inflammatory Th17 cells [6, 49, 51]. IDO plays a vital role
in this conversion [2, 39]. IDO stimulates Treg bystander
suppressor activity and simultaneously blocks the IL-6
production that is required to convert Tregs into Th17-like
T cells [2, 39]. The phenotype of reprogrammed Tregs after
IDO-blocking have been described as similar to that of
‘‘polyfunctional’’ T-helper cells co-expressing IL-17, IL-
22, IL-2 as well as TNF-a [39]. Thus, IDO suppression of
pro-inflammatory processes may dominantly block effector
T-cell responses to antigens encountered. Conversely,
absence of IDO activity may not elicit local Treg sup-
pression even when strong pro-inflammatory stimuli are
present.
Finally, it was recently shown that IDO has a non-
enzymic function that contributes to TGF-b driven toler-
ance in non-inflammatory contexts [29].
IDO and cancer
IDO expression is widely deregulated in cancer patients.
IDO may contribute in a critical manner to inhibit or ter-
minate inflammation and are highly overexpressed in
cancer [14, 22].
In cancer patients, IDO elevation occurs in a subset of
plasmacytoid DC in tumor-draining lymph nodes [26]. In
addition, IDO may be expressed within the tumor by tumor
cells as well as tumor stromal cells, where it inhibits the
effector phase of immune responses [45]. Activation of
IDO in either tumor cells or nodal regulatory DC each
appears to be sufficient to facilitate immune escape of
tumors [24]. In this regard, it has been described that
expression of IDO in tumor cells is associated with an
impaired prognosis [46]. In a murine model, it was
observed that tumor cells transfected with IDO became
resistant to immune eradication, even in mice in which a
fully protective immune response had been established by
immunization [45]. IDO-expressing CD19? plasmacytoid
DC isolated from tumor-draining LN mediate profound
immune suppression and T-cell anergy in vivo [25, 37],
whereas plasmacytoid DC from normal LNs and spleen do
not express IDO. In this respect, it should be noted that
very few cells constitutively express IDO in normal lym-
phoid tissue except in the gut. It is believed that constitu-
tive IDO expression in DC in tumor-draining LN is
induced by stimulation from Tregs migrating from the
tumor to the draining LN. Tregs have been shown to induce
IDO via cell-surface expression of CTLA-4 [44]. The
induction of IDO converts the tumor-draining LN from an
immunizing into a tolerizing milieu.
All in all, IDO is a critical cellular factor contributing to
immune suppression and as such is a crucial mechanism in
cancer. Hence, IDO has become a very attractive target for
the design of new anticancer drugs and several IDO
inhibitors are under investigation in preclinical as well as in
clinical studies [16]. In particular, the compound 1-methyl-
tryptophan (1MT) has been widely studied as an inhibitor
of IDO activity. Interestingly, recent studies have shown
that the racemer D-1-MT has superior antitumor activity
compared to the racemer L-1-MT [13]. A novel indole-
amine 2,3-dioxygenase (IDO)-like protein designated
IDO2 was recently discovered [20]. IDO2 functions like
IDO in tryptophan catabolism, but it has been found that
D-1MT but not the L-1MT isomer selectively and potently
inhibits IDO2 activity suggesting that IDO2 activity may
have a role in the inhibition of immune responses to
tumors. In this respect, IDO2 expression has been found in
human tumors, including gastric, colon, renal, and in
pancreatic tumors IDO2 expression have been found both
in tumor cells as well as in immune cells in tumor-draining
LN [47]. It is not yet known to what extent each isoform of
IDO contributes to tumor-related immune suppression and
how much clinical benefit (or autoimmune toxicity) tar-
geting one isoform over another confers. Another unknown
is whether IDO inhibitors influence other pathways not
directly linked to IDO.
CD8 responses against IDO
Despite the fact that neoplastic transformation is asso-
ciated with the expression of immunogenic antigens, the
immune system often fails to respond effectively and
becomes tolerant toward these antigens [21]. As descri-
bed above IDO plays a critical role in the tolerance
induction and immune suppression of anti-cancer
immune responses. We sat out to determine if and how
IDO itself serve as target for specific T-cell responses,
which may be exploited for immune therapy. This was
done by identifying and characterizing specific T cells
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spontaneously present among peripheral blood mononu-
clear cells (PBMC) isolated from cancer patients of
different origin. In this regard, we described that pep-
tides comprised in the IDO protein sequence are spon-
taneously recognized by cytotoxic T cells (CTL) in
cancer patients (Fig. 1) [40].
First, we identified HLA-restricted peptides within the
IDO protein to which spontaneous T-cell reactivity were
detected in patients suffering from unrelated tumor types,
i.e., melanoma, renal cell carcinoma and breast cancer by
flow cytometry using HLA/peptide tetramers as well as in
ELISPOT assays after in vitro stimulation but also in direct
ex vivo assays. Such IDO-reactive CD8? T cells were
peptide-specific, cytotoxic effector cells. Thus, IDO-spe-
cific T cells effectively lysed IDO? cancer cell lines of
different origin, such us colon carcinoma, melanoma, and
breast cancer as well as directly ex vivo enriched leukemia
cells. IDO driven immune suppression is a general mech-
anism that has been described in a variety of human can-
cers and the immune responses against IDO seem likewise
to be relevant in cancers of unrelated origin, which
emphasize the immunotherapeutic potential of IDO.
However, even more distinctive was our finding that IDO-
specific CTL recognized and killed IDO?, mature DC;
hence, IDO-specific T cells were in addition able to kill
immune-regulatory cells. We could at first not detect
spontaneous responses against IDO in the control group of
healthy individuals. Thus, although IDO has immune
suppressive functions, the constitutive up regulation of
IDO expression in cancer patients seemed to induce IDO-
specific T-cell responses.
IDO is playing a crucial role in immune regulation and
is inducible under normal physiological conditions. Thus,
we found the apparent lack of tolerance against IDO
intriguing, since it suggested a more general role of IDO-
specific T cells in the regulation of the immune system. We
hypothesized that such cells could take part in the control
of immune homeostasis; IDO-specific CD8? T cells could
play an important role by eliminating IDO? cells thereby
suppressing and/or delaying local immune suppression.
Hence, we continued our search for possible IDO-specific
T-cell responses in healthy donors and found that circu-
lating IDO-specific, cytotoxic CD8? T cells indeed were
present in healthy donors although not as frequent as in
patients with cancer [41]. Furthermore, we were able to
directly link the up regulation of IDO with IDO-specific T
cells by showing that the addition of IDO-inducing medi-
ators like IFN-c and CpG ODN generated measurable
numbers of CD8? IDO-specific T cells among PBMC. To
examine a possible immune-regulatory effect of IDO-spe-
cific T cells, we examined their effect on T-cell immunity
against viral or tumor-associated antigens. In this respect,
we found that the presence of IDO-specific CD8? T cells
boosted CD8? T-cell responses against other antigens
probably by eliminating IDO? suppressive cells (Fig. 2).
Consequently, we suggested terming IDO-specific T cells
‘‘supporter T cells’’ (Tsup) due to their immune enhancing
function [41].
IDO expression contributes to the strength and duration
of a given immune response due to its inflammation-
induced counter-regulatory function. Thus, any ‘‘support-
ive’’ effect of IDO-specific T cells on other immune cells
Fig. 1 Principle of the processing pathway of IDO peptides by IDO-
expressing cells (red), for example, tumor cells or dendritic cells and
the subsequent recognition by specific CD8 T cells (green; here
entitled a ‘‘supporter T cell’’ (Tsup).The epitopes recognized by the T
cells are short IDO-derived peptides resulting from the degradation of
intracellular IDO protein, which are presented on the cell surface of
HLA molecules. T cells receive an activation signal through their
T-cell receptor complex, leading to a variety of functional conse-
quences, including release of cytokines and cytotoxic molecules
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may well be mediated in several direct and indirect man-
ners. In this respect, the level of tryptophan was elevated,
the frequency of Tregs decreased, and the frequency of IL-
17 producing cells increased when IDO-specific T cells
were present, which taken together suggest an overall
decrease in IDO activity. Furthermore, IDO-specific T cells
increased the overall production of both IL-6 as well as the
other pro-inflammatory cytokine TNF-a. In contrast, we
observed a decrease in IL-10. Another possible effect of
IDO-specific T cells could be mediated through the
metabolites of tryptophan, which have been shown to be
directly toxic to CD8? T cells and CD4? Th1 cells [11],
but not Th2 cells. Hence, increased IDO activity seems to
tilt helper T-cell polarization toward a Th2 phenotype [48].
The presence of activated IDO-specific, cytotoxic T cells
may screw the Th-response in a Th1-direction. Finally, it
should be noted that IDO? cells may be immune sup-
pressive by other means than by the expression of IDO.
Hence, the same cells might express, for example, Argi-
nase, PD-L1 or immune-regulatory cytokines (e.g., IL-10
and TGF-b). Hence, IDO-specific, cytotoxic T cells may
not only reduce IDO-mediated suppression directly but in
addition further immune suppression mediated by IDO?
regulatory cells.
Recently, we identified spontaneous CD8? T-cell reac-
tivity against the IDO analogue IDO2 in peripheral blood
of both healthy donors and cancer patients [42].
Furthermore, we confirmed that IDO2-reactive CD8? T
cells were peptide-specific, cytotoxic effector T cells.
Hence, isolated and expanded IDO2-specific T cells
effectively lysed cancer cell lines of different origin, that
is, colon carcinoma cells as well as breast cancer cells.
However, IDO2-specific T cells did not seem to kill mel-
anoma cells although they expressed IDO2. At least, we
did not observe killing of three different IDO2? melanoma
cell lines. Likewise, IDO2-specific T cells did not seem to
‘‘support’’ other immune responses in the same way as
IDO-specific, cytotoxic T cells. Hence, the function and
potential role of the IDO2-specific class-I-restricted lym-
phocytes present in peripheral blood still need to be
resolved.
CD4 responses against IDO
We speculated that CD4? IDO-specific T cells releasing
pro-inflammatory cytokines may play a role in the early
phases of an immune response as a counter-response to the
induced immune suppression facilitated by IDO? cells.
Hence, IDO-specific Th1-cells may delay local immune
suppression if the activation of an IDO-specific CD4? Th1-
response could overcome the immune suppressive actions
of the IDO protein, which are otherwise a result of the early
expression of IDO in maturing DC or macrophages. Hence,
(B)
(A)
Fig. 2 IDO-specific T cells are
able to boost specific immunity
against virus or tumor antigens
in human PBMC. a When
stimulating PBMC with a
known HLA-restricted T-cell
virus epitope and IL-2, epitope-
specific T cells begin to expand
due to activation by antigen
presenting cells (APC). In
response to the subsequent
production of cytokines like
INF-c, IDO expression is
induced and IDO-expressing
APC inhibit further expansion
of virus-specific T cells both
directly and indirectly through
activation of Tregs. b The
addition of cytotoxic, IDO-
specific T cells (Tsup) removes
immune suppressive cells from
the PBMC culture thereby
facilitating further expansion of
virus-specific T cells
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we went on to analyze if CD4? T cells naturally recognized
IDO. Indeed, identified detectable numbers of specific
CD4? T cells both in cancer patients as well as healthy
individuals [23].
We found that such IDO-specific CD4? T cells
released INF-c as well as TNF-a. Although, we were able
to detect both INF-c and TNF-a response toward IDO in
healthy donors, the responses were more frequent in
cancer patients. The cancer relevance of these CD4? T
cells were further underlined, since IDO-reacting T cells
in addition react toward DC pulsed with IDO? tumor
lysates. Interestingly, we detected a correlation between
patients harboring CD4 and CD8 responses against IDO,
which that class-I- and class-II-restricted IDO responses
co-develop.
Furthermore, we detected frequent IDO-specific CD4?
T-cell responses when examining for IL-17 release upon
stimulation with the IDO-derived CD4 epitope. IL-17 has
been the focus of great interest recently since the produc-
tion of IL-17 is characterized to a subset of CD4? T-helper
cells (Th17 cells). One of the main roles of Th17 cells is
believed to be promoting host defense against infectious
agents. Th17 cells are thought to be particularly important
in maintaining barrier immunity at mucosal surfaces such
as in the lungs, gut, and skin [28]. Interestingly, IDO is
expressed at high levels in the gastrointestinal tract,
although its precise role in intestinal immunity is not well
understood [7]. One could speculate that a fraction of the
Th17 that are highly prevalent at the mucosal tissues of
healthy individuals [28] is recognizing IDO; however, this
is yet to be established. Additionally, it is well described
that Th17 cells contribute to autoimmunity [6]. In cancer,
Th17 cells might have a protective role in tumor immu-
nopathology by promoting antitumor immunity. Tumor-
infiltrating Th17 cells express other cytokines in addition to
IL-17, which might be functionally relevant [18]. A large
fraction of Th17 cells produce high levels of effector
cytokines such as IL-2, INF-c as well as TNF [51]. IDO-
specific Th17 cells seemed to exhibit a similar effector
T-cell cytokine profile [23]. We could in contrast not detect
any release of the Th2 cytokine IL-4 in response to the
IDO-derived peptide [23].
It was recently suggested that the Foxp3? Treg cell
lineage in addition to immune suppression have an unap-
preciated helper role [38]. These ‘‘Th17-like effector cells’’
were distinguished by their unique ability to deliver help
immediately and spontaneously, without needing prior
priming or pre-activation. It was suggested that these CD4
lineage cells correspond to a pool of constitutively primed
‘‘first responder’’ cells [38]. IDO plays an important role in
this conversion of Foxp3? Tregs to Th17-like effector cells
[2, 39]. Thus, it is possible that IDO-specific T cells could
in addition belong to a Foxp3? lineage of constitutively
primed ‘‘first responder’’ Th17-like T cells; however, it
should be strengthen that this is speculation.
Naturally, some CD4-positive IDO-specific T cells
could in addition be immune suppressive Tregs. It would
be obvious that IDO-specific Tregs may enhance the IDO-
mediated immune suppression protecting cells from an
immune attack. In this regard, we have previously descri-
bed specific regulatory CD8? T cells in cancer patients,
which recognized the immune suppressive Heme Oxy-
genase-1 [1]. IL-10 is mainly expressed by Tregs that have
been defined as a specialized subpopulation of T cells that
act to suppress activation of the immune system and
thereby maintain immune system homeostasis and toler-
ance to self-antigens [34, 35]. We could in addition in some
donors detect IL-10 release in response to the IDO-derived
CD4 epitope peptide. Hence, the role of IDO-specific
CD4? T cells in immune-regulatory networks may be a
complex balance between activation and inhibition
depending on the microenvironment. Interestingly, in some
donors we detected background IL-10 release in in vitro
pre-stimulated ELISPOT assays. This enabled us to rec-
ognize that stimulation with the IDO-derived peptide in
two healthy donors triggered an overall suppression of IL-
10. In this regard, we have previously observed a decrease




IDO may exhibit its immune inhibitory functions both in
the activation phases (in the draining lymph node) as well
as in the effector phases (at the site of the tumor). With
regard to the latter, IDO may even by induced as an
inflammation-induced counter-regulatory mechanism.
Counter-regulatory responses are important in the immune
system as they help to limit the intensity and extent of
immune responses, which otherwise could cause damage to
the host. However, with regard to anti-cancer immuno-
therapy, counter-regulatory responses antagonize the abil-
ity to create an intense immune response against the tumor.
Counter-regulation differs from tolerance in the sense that
counter-regulation is a secondary event, elicited only in
response to immune activation. IDO is known to be
induced by both type I and II interferons, which are likely
to be found at sites of immune activation and inflammation
[31, 36]. In this respect, it should be mentioned that the
susceptibility of tumor cells to lysis by IDO-reactive T
cells were increased by pre-incubation with IFN-c [40].
Hence, in cancer immune therapy, the boosting of IDO-
specific immunity could have both direct and indirect
Cancer Immunol Immunother (2012) 61:1289–1297 1293
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effects (Fig. 3). First of all, IDO-specific, cytotoxic T cells
are able to directly recognize and kill IDO? cancer cells. In
fact, it may even be speculated that the measurable reac-
tivity to this antigen in normal individuals contributes to
immune surveillance against cancer. Furthermore, the
induction of IDO-specific immune responses by therapeutic
measures could function highly synergistic with additional
anti-cancer immune therapy not only by eliminating cancer
cells but in addition immune suppressive cells. By defini-
tion, anti-cancer immune therapies aim at the induction of
an immunological activation and inflammation. The ther-
apy aims to induce as much immune activation as possible
(within the limits of acceptable toxicity), and, accordingly,
immune suppressive counter-regulation is not desired.
Adoptive transfer of ex vivo expanded tumor-infiltrating
lymphocytes (TIL) after host lymphodepletion has the
potential to significantly improve the prognosis of patients
with metastatic melanoma. The impressive clinical
responses associated with adoptive transfer of TIL [9] urge
that this strategy is pursued and investigated for the treat-
ment of other types of cancer. In this regard, patient IDO-
specific T cells isolated and expanded from PBMC may
well be an interesting supplement to the ongoing adaptive
T-cell transfer strategies.
It goes without saying that the possible introduction of
autoimmunity and toxicity are the major worries when
targeting a molecule like IDO. However, the circulation of
a measurable number of IDO-specific T cells did not seem
to cause autoimmunity. Furthermore, since IDO-specific T
cells can be introduced by IFN or CpG this appears to be
under solid control. In this regard, an interesting aspect of
IDO is that systemic inactivation at the organism level,
either pharmacologically or genetically, does not appear to
cause autoimmunity [19].
We believe that the findings that presented here justified
and warranted clinical testing to evaluate the efficiency and
safety of IDO-based vaccinations. Hence, we initiated a phase
I vaccination study, which is ongoing (from June 2010) at
Center for Caner Immune Therapy, Copenhagen University
Hospital, Herlev, in which patients with non-small cell
lung cancer (NSCLC) are vaccinated with a IDO-derived
peptide with Montanide adjuvant (www.clinicaltrials.gov;
NCT01219348).
Additional pathogenic settings
It has been suggested that IDO may rather be involved in
tolerance to non-self-antigens than self-antigens in situa-
tions where immune non-responsiveness may be important,
for example, during pregnancy [19]. In this respect,
induction of IDO? immune-regulatory dendritic cells (DC)
have been described to occur during infection of DCs with
viruses and intracellular pathogens. In Listeria monocyt-
ogenes infections, such IDO? DC seems to be involved in
protection of the host from granuloma breakdown and
pathogen dissemination in advanced human listeriosis.
Likewise, it was recently described that IDO is increased in
lymph nodes in cutaneous Leishmania major infection
[17]. IDO is implicated in suppressing T-cell immunity to
parasite antigens and IDO inhibition reduced local
inflammation and parasite burdens, which suggest that IDO
were of benefit for the pathogen, not the host. During HIV
Fig. 3 Vaccine induced IDO-
specific T cells might kill IDO?
suppressive antigen presenting
cells (APC) as well as IDO?
cancer cells both at the tumor
site and in the draining lymph
nodes. IDO may exhibit its
immune inhibitory functions
both in the activation phases (in
the draining lymph node) as
wells as in the effector phases
(at the site of the tumor). Hence,
an IDO-based cancer vaccine
might work directly at the tumor
site by the attack of cancer cells
as well as stromal cells as well
as in the draining lymph node
by the attack of IDO-expressing
regulatory cells
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infection, multiple mechanisms involving both viral and
cellular components contribute to enhance IDO expression
and activity in an uncontrolled manner. Among others,
HIV inhibits T-cell proliferation by inducing IDO in
plasmacytoid DC and macrophages [5]. Furthermore, it
was recently described that IDO is increased in hemodi-
alysis (HD) patients compared to healthy donors [10].
Furthermore, IDO suppresses adaptive immunity in HD
patients as it is assessed by the response to HBV vacci-
nation. Hence, the targeting of IDO could have synergistic
effects in anti-viral immune therapy, for example, in
Hepatitis B vaccines.
The fact that IDO may be involved in tolerance to non-
self-antigens might have major implications for IDO-based
immune therapy as boosting immunity to neoantigens, but
not normal self-antigens, by triggering IDO-specific T cells
is very attractive. Since IDO-expressing cells might
antagonize the desired effects of other immunotherapeutic
approaches targeting IDO-expressing cells by vaccination
would consequently be easily implementable and highly
synergistic with such therapeutic measures. However, it
was recently described that although IDO might play bio-
logically important roles in the host response to diverse
intracellular infections like Toxoplasma gondii, leishman-
iasis, and herpes simplex virus, the nature of this role that
being antimicrobial or immunoregulatory might depend on
the pathogen. Hence, IDO inhibition might not always
benefit the host. In this regard, IDO inhibition during
murine toxoplasmosis led to increased mortality with
increased parasite burdens [8]. This should naturally been
taken into account when exploring the possible use of IDO-
specific T cells in the clinic.
Finally, it should be mentioned that CD14? monocytes
are major CMV target cells in vivo. CMV is the most
immune dominant antigen to be encountered by the human
immune system [43]. Monocytes are responsible for dis-
semination of the virus throughout the body during acute and
late phase of infection. CMV has been shown to induce IDO
expression in monocytes, which has been suggested to
confer an advantage to CMV-infected monocytes to escape
T-cell responses [12]. The CD8? T-cell response to CMV
typically comprises a sizeable percentage of the CD8? T-cell
repertoire in CMV-seropositive individuals [15]. In light of
this, it is possible that IDO-specific T cells might function as
support for the constitutive anti-CMV CD8? T-cell
response. Naturally, this can only be speculation, but notably
we found that the presence of IDO-specific CD4? T-cell
responses correlated to the presence of CMV-responses [23].
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